September 16, 2010
News Release 10-103
Inv. No. 332-520
Contact: Peg O'Laughlin, 202-205-1819

USITC RELEASES ADVICE ON THE ELIMINATION OF TARIFFS ON CERTAIN PHARMACEUTICAL PRODUCTS AND CHEMICAL INTERMEDIATES

The U.S. International Trade Commission (USITC) today released the results of its investigation providing information and advice to the President concerning approximately 735 pharmaceutical products and chemical intermediates for which the Administration is proposing to eliminate duties. The items under investigation are used primarily for the production of pharmaceuticals.

The products would be added to the Pharmaceutical Appendix to the Harmonized Tariff Schedule of the United States (HTS), which was created as part of the Uruguay Round Agreements and already covers approximately 9,500 products. The United States and 21 other major trading countries agreed during the Uruguay Round to eliminate duties on pharmaceuticals and to periodically conduct reviews to identify additional products to be covered by the initiative. If added to the Appendix, the products included in the new USITC investigation would receive duty-free treatment.

The investigation, Pharmaceutical Products and Chemical Intermediates, Fourth Review: Advice Concerning the Addition of Certain Products to the Pharmaceutical Appendix to the HTS (Inv. No. 332-520), was requested by the U.S. Trade Representative (USTR) in a letter received May 28, 2010. The USITC submitted its report to the USTR on September 1, 2010.

As requested, the USITC provided a summary description of the products contained in the existing Pharmaceutical Appendix and the modifications to be made to that Appendix; an explanation of the relationship between the various elements in the Appendix and the HTS; and an estimate of current U.S. imports and, where possible, current U.S. exports of the products included in the existing Pharmaceutical Appendix and the proposed additions to the Appendix.

Pharmaceutical Products and Chemical Intermediates, Fourth Review: Advice Concerning the Addition of Certain Products to the Pharmaceutical Appendix to the HTS (Investigation No. 332-520, USITC Publication 4181, September 2010) is available on the USITC's Internet site at http://www.usitc.gov/publications/332/pub4181.pdf. A CD-ROM of the report may be requested by e-mailing pubrequest@usitc.gov, calling 202-205-2000, or contacting the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. Requests may also be faxed to 202-205-2104.

USITC general factfinding investigations, such as this one, cover matters related to tariffs or trade and are generally conducted at the request of the USTR, the House Committee on Ways and Means, or the Senate Committee on Finance. The resulting reports convey the Commission's objective findings and independent analyses on the subjects investigated. The Commission makes no recommendations on policy or other matters in its general factfinding reports. Upon completion of each investigation, the USITC submits its findings and analyses to the requester. General factfinding investigation reports are subsequently released to the public unless they are classified by the requester for national security reasons.

-- 30 --